These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29396328)

  • 41. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
    Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
    J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Which type of breast cancers is undetectable on ring-type dedicated breast PET?
    Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
    Clin Imaging; 2018; 51():186-191. PubMed ID: 29859482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.
    Kolesnikov-Gauthier H; Vanlemmens L; Baranzelli MC; Vennin P; Servent V; Fournier C; Carpentier P; Bonneterre J
    Breast Cancer Res Treat; 2012 Jan; 131(2):517-25. PubMed ID: 22037787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
    Pahk K; Kim S; Choe JG
    Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.
    Nuvoli S; Galassi S; Gelo I; Rocchitta G; Fancellu A; Serra PA; Madeddu G; Spanu A
    Oncol Rep; 2018 May; 39(5):2055-2062. PubMed ID: 29512735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.
    Ueda S; Saeki T; Shigekawa T; Omata J; Moriya T; Yamamoto J; Osaki A; Fujiuchi N; Misumi M; Takeuchi H; Sakurai T; Tsuda H; Tamura K; Ishida J; Abe Y; Imabayashi E; Kuji I; Matsuda H
    Int J Clin Oncol; 2012 Jun; 17(3):276-82. PubMed ID: 21830087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
    Schwarz-Dose J; Untch M; Tiling R; Sassen S; Mahner S; Kahlert S; Harbeck N; Lebeau A; Brenner W; Schwaiger M; Jaenicke F; Avril N
    J Clin Oncol; 2009 Feb; 27(4):535-41. PubMed ID: 19075273
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of
    Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
    AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
    [No Abstract]   [Full Text] [Related]  

  • 58. Preoperative FDG-PET for axillary metastases in patients with breast cancer.
    Chung A; Liou D; Karlan S; Waxman A; Fujimoto K; Hagiike M; Phillips EH
    Arch Surg; 2006 Aug; 141(8):783-8; discussion 788-9. PubMed ID: 16924086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.
    Kitajima K; Nakatani K; Yamaguchi K; Nakajo M; Tani A; Ishibashi M; Hosoya K; Morita T; Kinoshita T; Kaida H; Miyoshi Y
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1661-1671. PubMed ID: 29754160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of radioactivity outside the field of view on image quality of dedicated breast positron emission tomography: preliminary phantom and clinical studies.
    Satoh Y; Imai M; Ikegawa C; Hirata K; Abo N; Kusuzaki M; Oyama-Manabe N; Onishi H
    Ann Nucl Med; 2022 Dec; 36(12):1010-1018. PubMed ID: 36207497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.